Durable response to crizotinib in a patient with lung adenocarcinoma harbouring low-level MET amplification but strong MET expression

被引：0
|
作者：
Riedel, R. [1 ]
Michels, S. [1 ]
Heydt, C. [2 ]
Nogova, L. [1 ]
Fischer, R. N. [1 ]
Abdulla, D. S. Y. [1 ]
Scheffler, M. [1 ]
Merkelbach-Bruse, S. [2 ]
Kobe, C. [3 ]
Schaefer, S. [2 ]
Buettner, R. [2 ]
Wolf, J. [1 ]
机构：
[1] Uniklin Koln, Klin Innere Med 1, Cologne, Germany
[2] Uniklin Koln, Inst Pathol, Cologne, Germany
[3] Uniklin Koln, Klin Nukl Med, Cologne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P910
引用
收藏
页码：295 / 296
页数：2
相关论文
共 50 条
  • [41] Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation
    Yao, Jing-hao
    Wang, An-sheng
    Wang, Xiao-jing
    Zhang, Lu
    Zhu, Yue
    Ou, Yu-rong
    Wang, Zi-shu
    Yang, Yan
    ONCOTARGETS AND THERAPY, 2019, 12 : 4261 - 4267
  • [42] Response to savolitinib in a patient with lung adenocarcinoma harboring a novel MET exon 14 skipping mutation
    Liu, Zhenkun
    Li, Pengfei
    Wu, Qiang
    Zhou, Qinghua
    ASIAN JOURNAL OF SURGERY, 2024, 47 (04) : 1851 - 1852
  • [43] Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib
    Berger, Lars-Arne
    Janning, Melanie
    Velthaus, Janna-Lisa
    Ben-Batalla, Isabel
    Schatz, Stefanie
    Falk, Markus
    Iglauer, Peter
    Simon, Ronald
    Cao, Ru
    Forcato, Claudio
    Manaresi, Nicolo
    Bramlett, Kelli
    Buson, Genny
    Hanssen, Annkathrin
    Tiemann, Markus
    Sauter, Guido
    Bokemeyer, Carsten
    Riethdorf, Sabine
    Reck, Martin
    Pantel, Klaus
    Wikman, Harriet
    Loges, Sonja
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : E243 - E246
  • [44] Identification of a high-level MET amplification in CTCs and cfTNA in an ALK-rearranged NSCLC patient developing evasive resistance to crizotinib
    Berger, L. -A.
    Velthaus, J. -L.
    Janning, M.
    Schatz, S.
    Falk, M.
    Iglauer, P.
    Simon, R.
    Cao, R.
    Bramlett, K.
    Buson, G.
    Petrini, E.
    Forcato, C.
    Tiemann, M.
    Sauter, G.
    Bokemeyer, C.
    Reck, M.
    Riethdorf, S.
    Pantel, K.
    Wikman, H.
    Loges, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 296 - 297
  • [45] Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib
    Zheng, Xuanxuan
    Zhang, Guowei
    Li, Peng
    Zhang, Mina
    Yan, Xiangtao
    Zhang, Xiaojuan
    Yang, Jinbo
    Li, Haixia
    Liu, Xiyang
    Ma, Zhiyong
    Wang, Huijuan
    LUNG CANCER, 2019, 129 : 72 - 74
  • [46] Severe acute interstitial lung disease induced by crizotinib therapy in a patient with c-Met amplification non-small cell lung cancer
    Ji Youxin
    Zhang Zhongfa
    Nie Keke
    Lan Ketao
    Geng Chuanxin
    Liu Shichao
    Zhang Ling
    Zhang Zongchun
    Sun Lei
    Zou Xiao
    中华医学杂志（英文版）, 2014, (08) : 1600 - 1600
  • [47] Severe acute interstitial lung disease induced by crizotinib therapy in a patient with c-Met amplification non-small cell lung cancer
    Ji Youxin
    Zhang Zhongfa
    Nie Keke
    Lan Ketao
    Geng Chuanxin
    Liu Shichao
    Zhang Ling
    Zhang Zongchun
    Sun Lei
    Zou Xiao
    CHINESE MEDICAL JOURNAL, 2014, 127 (08) : 1600 - 1600
  • [48] A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
    Zhu, You-cai
    Wang, Wen-xian
    Xu, Chun-wei
    Zhuang, Wu
    Song, Zheng-bo
    Du, Kai-qi
    Chen, Gang
    Lv, Tang-feng
    Song, Yong
    CANCER BIOLOGY & THERAPY, 2018, 19 (12) : 1097 - 1101
  • [49] Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation A case report
    Tan, Xiang
    Dai, Lei
    Wang, Yongyong
    Liang, Guanbiao
    Yang, Nuo
    Chen, Mingwu
    MEDICINE, 2017, 96 (47)
  • [50] Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
    Takamori, Shinkichi
    Matsubara, Taichi
    Fujishita, Takatoshi
    Ito, Kensaku
    Toyozawa, Ryo
    Seto, Takashi
    Yamaguchi, Masafumi
    Okamoto, Tatsuro
    THORACIC CANCER, 2021, 12 (06) : 978 - 980
12345